Cite
Comprehensive assessment of the disputed RET Y791F variant shows no association with medullary thyroid carcinoma susceptibility.
MLA
Toledo, Rodrigo A., et al. “Comprehensive Assessment of the Disputed RET Y791F Variant Shows No Association with Medullary Thyroid Carcinoma Susceptibility.” Endocrine-Related Cancer, vol. 22, no. 1, Feb. 2015, pp. 65–76. EBSCOhost, https://doi.org/10.1530/ERC-14-0491.
APA
Toledo, R. A., Hatakana, R., Lourenço, D. M., Jr, Lindsey, S. C., Camacho, C. P., Almeida, M., Lima, J. V., Jr, Sekiya, T., Garralda, E., Naslavsky, M. S., Yamamoto, G. L., Lazar, M., Meirelles, O., Sobreira, T. J. P., Lebrao, M. L., Duarte, Y. A. O., Blangero, J., Zatz, M., Cerutti, J. M., … Toledo, S. P. A. (2015). Comprehensive assessment of the disputed RET Y791F variant shows no association with medullary thyroid carcinoma susceptibility. Endocrine-Related Cancer, 22(1), 65–76. https://doi.org/10.1530/ERC-14-0491
Chicago
Toledo, Rodrigo A, Roxanne Hatakana, Delmar M Lourenço Jr, Susan C Lindsey, Cleber P Camacho, Marcio Almeida, José V Lima Jr, et al. 2015. “Comprehensive Assessment of the Disputed RET Y791F Variant Shows No Association with Medullary Thyroid Carcinoma Susceptibility.” Endocrine-Related Cancer 22 (1): 65–76. doi:10.1530/ERC-14-0491.